An update of advanced nanoplatforms for glioblastoma multiforme management

Amaral, Mariana; Cruz, Nuno; Rosa, Ana; Nogueira, Beatriz Maria Dias; Costa, Diogo Alpuim; Santos, Filipe Neves dos; Brazão, Mariana; Policarpo, Pedro; Mateus, Rita; Kobozev, Yan; Reis, Catarina Pinto

doi:10.17179/excli2021-4393

Cited by 9 publications

(7 citation statements)

References 126 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GBM is one of the most aggressive forms of brain cancer that affects thousands of people and is notable for its poor prognoses. Since current strategies lack specificity, which leads to toxicity in healthy tissues and does not inhibit recurrences, targeted nanomedicines (NMeds) are being widely investigated as promising new tools, as demonstrated by an abundance of reviews in the last two years [ 70 , 71 , 72 , 73 , 74 , 75 , 76 ]. One of the most important aspects to consider when optimising a targeted NMed is selecting an appropriate targeting ligand.…”

Section: Discussionmentioning

confidence: 99%

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

et al. 2022

View full text Add to dashboard Cite

Glioblastoma Multiforme (GBM) is a devastating disease with a low survival rate and few efficacious treatment options. The fast growth, late diagnostics, and off-target toxicity of currently used drugs represent major barriers that need to be overcome to provide a viable cure. Nanomedicines (NMeds) offer a way to overcome these pitfalls by protecting and loading drugs, increasing blood half-life, and being targetable with specific ligands on their surface. In this study, the FDA-approved polymer poly (lactic-co-glycolic) acid was used to optimise NMeds that were surface modified with a series of potential GBM-specific ligands. The NMeds were fully characterised for their physical and chemical properties, and then in vitro testing was performed to evaluate cell uptake and GBM cell specificity. While all targeted NMeds showed improved uptake, only those decorated with the-cell surface vimentin antibody M08 showed specificity for GBM over healthy cells. Finally, the most promising targeted NMed candidate was loaded with the well-known chemotherapeutic, paclitaxel, to confirm targeting and therapeutic effects in C6 GBM cells. These results demonstrate the importance of using well-optimised NMeds targeted with novel ligands to advance delivery and pharmaceutical effects against diseased cells while minimising the risk for nearby healthy cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 51–53 Early-phase trials are ongoing. 54 However, the complex and heterogeneous nature of GB requires these technologies to be tested on advanced models of the disease, such as patient-derived organoids or xenografts, before considering translation to the clinic.…”

Section: Novel Lines Of Research In Glioblastoma and Gliomas In Generalmentioning

confidence: 99%

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

Pineda¹,

Doménech²,

Hernández³

et al. 2023

OTT

View full text Add to dashboard Cite

Virtually all glioblastomas treated in the first-line setting will recur in a short period of time, and the search for alternative effective treatments has so far been unsuccessful. Various obstacles remain unresolved, and no effective salvage therapy for recurrent glioblastoma can be envisaged in the short term. One of the main impediments to progress is the low incidence of the disease itself in comparison with other pathologies, which will be made even lower by the recent WHO classification of gliomas, which includes molecular alterations. This new classification helps refine patient prognosis but does not clarify the most appropriate treatment. Other impediments are related to clinical trials: glioblastoma patients are often excluded from trials due to their advanced age and limiting neurological symptoms; there is also the question of how best to measure treatment efficacy, which conditions the design of trials and can affect the acceptance of results by oncologists and medicine agencies. Other obstacles are related to the drugs themselves: most treatments cannot cross the blood-brain-barrier or the brain-to-tumor barrier to reach therapeutic drug levels in the tumor without producing toxicity; the drugs under study may have adverse metabolic interactions with those required for symptom control; identifying the target of the drug can be a complex issue. Additionally, the optimal method of treatment – local vs systemic therapy, the choice of chemotherapy, irradiation, targeted therapy, immunotherapy, or a combination thereof – is not yet clear in glioblastoma in comparison with other cancers. Finally, in addition to curing or stabilizing the disease, glioblastoma therapy should aim at maintaining the neurological status of the patients to enable them to return to their previous lifestyle. Here we review currently available treatments, obstacles in the search for new treatments, and novel lines of research that show promise for the future.

show abstract

“…In addition, biofilms can be modified to obtain additional functions. The method of NP core preparation often depends on the core material and personalization and has been reported in several papers 109,110 , therefore, it is not reviewed here. The Methods of Biofilm Extraction…”

Section: The Fabrication Of Biomimetic Nanoparticlesmentioning

confidence: 99%

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Yang¹,

Cheng²,

Luo³

et al. 2023

IJN

View full text Add to dashboard Cite

Glioblastoma (GBM), a highly aggressive form of brain cancer, is considered one of the deadliest cancers, and even with the most advanced medical treatments, most affected patients have a poor prognosis. However, recent advances in nanotechnology offer promising avenues for the development of versatile therapeutic and diagnostic nanoplatforms that can deliver drugs to brain tumor sites through the blood-brain barrier (BBB). Despite these breakthroughs, the use of nanoplatforms in GBM therapy has been a subject of great controversy due to concerns over the biosafety of these nanoplatforms. In recent years, biomimetic nanoplatforms have gained unprecedented attention in the biomedical field. With advantages such as extended circulation times, and improved immune evasion and active targeting compared to conventional nanosystems, bionanoparticles have shown great potential for use in biomedical applications. In this prospective article, we endeavor to comprehensively review the application of bionanomaterials in the treatment of glioma, focusing on the rational design of multifunctional nanoplatforms to facilitate BBB infiltration, promote efficient accumulation in the tumor, enable precise tumor imaging, and achieve remarkable tumor suppression. Furthermore, we discuss the challenges and future trends in this field. Through careful design and optimization of nanoplatforms, researchers are paving the way toward safer and more effective therapies for GBM patients. The development of biomimetic nanoplatform applications for glioma therapy is a promising avenue for precision medicine, which could ultimately improve patient outcomes and quality of life.

show abstract

An update of advanced nanoplatforms for glioblastoma multiforme management

Cited by 9 publications

References 126 publications

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Contact Info

Product

Resources

About